Gilead Sciences @GileadSciences · 24 Aug 2026
#GileadNews: The European Commission (EC) expands role of our treatment for first-line metastatic triple-negative breast cancer (mTNBC), establishing it as the first and only antibody-drug conjugate for first-line treatment across PD-(L)1 status. https://t.co/qf94xxeTbG https://t.co/4NrQ3WWQZ8
1 647Views
5Likes
2Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
1.00×vs this author's median1 647 views is typical
43Percentile for this authorof 7 recent posts
0.60×vs 10K–100K median2 747 views is typical
2.28%Reachviews ÷ followers
0.42%Engagement rateof viewers reacted